Russia acts to prevent anti-HIV drugs shortages in domestic market

24 October 2022

The Russian government is planning to take measures to prevent a shortage of anti-HIV drugs in the country by the increased procurements drugs and their more active supplies to the domestic market, reports The Pharma Letter’s local correspondent.

Recently Russian media reported about the shortage of Tivicay (dolutegravir), an anti-HIV drugs from the UK’s GSK (LSE: GSK) in the Russian market, which is mainly due to a significant decline of the volume of its procurements by the state.

According to analysts, as of now, patients in different regions of Russia, have faced shortage of dolutegravir (DTG), which has no analogues in Russia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical